Pyoderma gangrenosum - Pioderma Gangrenoso
Il Pioderma Gangrenoso (Pyoderma gangrenosum) è una rara malattia infiammatoria della pelle in cui pustole o noduli dolorosi diventano ulcere che crescono progressivamente. pioderma gangrenoso (pyoderma gangrenosum) non è infettivo. I trattamenti possono includere corticosteroidi, ciclosporina o vari anticorpi monoclonali. Sebbene possa colpire persone di qualsiasi età, colpisce soprattutto le persone tra i 40 e i 50 anni.
☆ Nei risultati della Stiftung Warentest 2022 dalla Germania, la soddisfazione dei consumatori con ModelDerm è stata solo leggermente inferiore rispetto alle consulenze di telemedicina a pagamento.
Sulla gamba di una persona affetta da colite ulcerosa.
References
Pyoderma gangrenosum è una rara condizione della pelle che provoca ulcere dolorose con bordi rossi o violacei. È classificata come una malattia infiammatoria e fa parte di un gruppo chiamato dermatosi neutrofile. La causa di pyoderma gangrenosum è complessa e coinvolge problemi con l'immunità sia innata che adattativa nelle persone geneticamente predisposte. Recentemente, i ricercatori si sono concentrati sul follicolo pilifero come potenziale punto di partenza della malattia.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum è una rara condizione della pelle che provoca ulcere estremamente dolorose. Anche se non ne comprendiamo appieno la causa, sappiamo che comporta un aumento dell’attività di alcune cellule immunitarie. Trattare la malattia non è ancora facile. Disponiamo di vari farmaci che sopprimono il sistema immunitario o ne modificano l'attività. Oltre a questi, ci concentriamo anche sul trattamento delle ferite e sulla gestione del dolore. I corticosteroidi e la ciclosporina sono spesso la prima scelta per il trattamento, ma ultimamente sono state condotte ulteriori ricerche sull'uso di terapie biologiche come gli inibitori del TNF-α. Questi farmaci biologici sono sempre più preferiti, soprattutto nei pazienti con altre condizioni infiammatorie, e vengono utilizzati nelle fasi iniziali del processo patologico.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
